<DOC>
	<DOCNO>NCT01594281</DOCNO>
	<brief_summary>This study ass efficacy safety Ranibizumab alone combination laser treatment vs. laser treatment alone Proliferative Diabetic Retinopathy . Efficacy primarily measure change area neovascularizations measure Fluorescein Angiography month 12 ( difference baseline value ) .</brief_summary>
	<brief_title>Multicenter 12 Months Clinical Study Evaluate Efficacy Safety Ranibizumab Alone Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone Proliferative Diabetic Retinopathy ( PRIDE )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Proliferative Diabetic Retinopathy BCVA ≥ 20 ETDRS letter Diabetes mellitus HbA1c ≤ 12 % ( =107 mmol/mol ) Proliferative vitreoretinopathy Clinically significant macular edema ( CSME ) Clinically non significant macular edema likely develop CSME NVD ≥ 2 DA multiple NVE combine area ≥ 2 DA involve macula Vitreous hemorrhage Vitreomacular traction Previous scatter PRP treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Panretinal photocoagulation</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>